

Resource Summary Report

Generated by ASWG on Aug 3, 2026

Structural Genomics Consortium

RRID:SCR_003890

Type: Tool

Proper Citation

Structural Genomics Consortium (RRID:SCR_003890)

Resource Information

URL: <http://www.thesgc.org/>

Proper Citation: Structural Genomics Consortium (RRID:SCR_003890)

Description: Charity registered in United Kingdom whose mission is to accelerate research in new areas of human biology and drug discovery. Not for profit, public-private partnership that carries out basic science of relevance to drug discovery whose core mandate is to determine 3D structures on large scale and cost effectively targeting human proteins of biomedical importance and proteins from human parasites that represent potential drug targets.

Abbreviations: SGC

Synonyms: Structural Genomics Consortium

Resource Type: organization portal, data or information resource, consortium, portal

Keywords: basic science, drug discovery, drug, structural genomics, genomics, 3d structure, protein, human parasite, drug target, structure, human protein, protocol, phylogenetic tree, histone tail, high-throughput protein crystallization, lex bubbling system, reagent, epigenetic probe, antibody, vector, plasmid, construct

Related Condition: Cancer, Diabetes, Obesity, Psychiatric disorder, Alzheimer

Funding: AbbVie ;
Boehringer Ingelheim ;
Canada Foundation for Innovation ;
Canadian Institutes of Health Research ;
Genome Canada ;
GlaxoSmithKline ;
Janssen ;
Lilly Canada ;
Novartis Research Foundation ;

Ontario Ministry of Economic Development Employment and Infrastructure ;
Pfizer ;
Takeda ;
Wellcome Trust

Availability: Restricted

Resource Name: Structural Genomics Consortium

Resource ID: SCR_003890

Alternate IDs: nlx_158220

Record Creation Time: 20220129T080221+0000

Record Last Update: 20260803T040349+0000

Ratings and Alerts

No rating or validation information has been found for Structural Genomics Consortium.

No alerts have been found for Structural Genomics Consortium.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 61 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Takeuchi K, et al. (2025) PI5P4K inhibitors: promising opportunities and challenges. The FEBS journal, 292(17), 4446.

Ballasy N, et al. (2025) A roadmap towards targeted differentiation of mouse trophoblast stem cells into cell types of the feto-maternal exchange surface. Stem cell research & therapy, 16(1), 371.

Dos Reis TF, et al. (2025) The GPCR antagonist PPTN synergizes with caspofungin providing increased fungicidal activity against Aspergillus fumigatus. Microbiology spectrum, 13(5), e0331824.

Funk JS, et al. (2025) Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations. Nature genetics, 57(1), 140.

Youhanna S, et al. (2025) Chemogenomic Screening in a Patient-Derived 3D Fatty Liver Disease Model Reveals the CHRM1-TRPM8 Axis as a Novel Module for Targeted Intervention. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(3),

e2407572.

Jiang J, et al. (2022) Systematic illumination of druggable genes in cancer genomes. *Cell reports*, 38(8), 110400.

Lesbon JCC, et al. (2022) A Screening of Epigenetic Therapeutic Targets for Non-Small Cell Lung Cancer Reveals PADI4 and KDM6B as Promising Candidates. *International journal of molecular sciences*, 23(19).

Krstic A, et al. (2021) A Chemo-Genomic Approach Identifies Diverse Epigenetic Therapeutic Vulnerabilities in MYCN-Amplified Neuroblastoma. *Frontiers in cell and developmental biology*, 9, 612518.

Hughes RE, et al. (2021) High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need. *Cell chemical biology*, 28(3), 338.

Yang T, et al. (2021) MalDA, Accelerating Malaria Drug Discovery. *Trends in parasitology*, 37(6), 493.

Criqui M, et al. (2020) Telomere dysfunction cooperates with epigenetic alterations to impair murine embryonic stem cell fate commitment. *eLife*, 9.

Perkail S, et al. (2020) BAP1 is a haploinsufficient tumor suppressor linking chronic pancreatitis to pancreatic cancer in mice. *Nature communications*, 11(1), 3018.

Vollmar M, et al. (2020) The predictive power of data-processing statistics. *IUCrJ*, 7(Pt 2), 342.

Bergqvist F, et al. (2020) Anti-Inflammatory Properties of Chemical Probes in Human Whole Blood: Focus on Prostaglandin E2 Production. *Frontiers in pharmacology*, 11, 613.

Westphal M, et al. (2020) Chemical Genetics Screen Identifies Epigenetic Mechanisms Involved in Dopaminergic and Noradrenergic Neurogenesis in Zebrafish. *Frontiers in genetics*, 11, 80.

Leiendecker L, et al. (2020) LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma. *EMBO molecular medicine*, 12(11), e12525.

Zwiggelaar RT, et al. (2020) LSD1 represses a neonatal/reparative gene program in adult intestinal epithelium. *Science advances*, 6(37).

Anastas JN, et al. (2019) Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. *Cancer cell*, 36(5), 528.

Hetu M, et al. (2019) Genomics for All: International Open Science Genomics Projects and Capacity Building in the Developing World. *Frontiers in genetics*, 10, 95.

Lieske J, et al. (2019) On-chip crystallization for serial crystallography experiments and on-chip ligand-binding studies. *IUCrJ*, 6(Pt 4), 714.